Alzamend Neuro, Inc.
ALZN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001677077
In the last 90 days, Alzamend Neuro, Inc. insiders filed 1 open-market purchase and 1 sale; 12 institutions reported holding it in 13F filings for Q2 2026, worth $3.26M in total; no superinvestor holds it.
Q2 2024 vs. Q1 2024
How the institutions holding Alzamend Neuro, Inc. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 13 | 16 | +3 |
| Shares | 387.1K | 380.1K | −6.97K (−1.8%) |
| Value | $386.8K | $150.5K | −$236.3K (−61.1%) |
New holders (5)
Institutions that held Alzamend Neuro, Inc. at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| CoreCap Advisors, LLC | 7,084 | $2.79K | 0.00% |
| UBS Group AG | 5,132 | $2.02K | 0.00% |
| Activest Wealth Management | 200 | $79 | 0.00% |
| Bank of America Corp | 95 | $38 | 0.00% |
| City State Bank | 40 | $16 | 0.00% |
Sold out (2)
Institutions that held Alzamend Neuro, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Virtu Financial LLC | 26,482 | $26.0K |
| Wells Fargo & Company | 39 | $39 |